Results 41 to 50 of about 459,727 (225)

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect

npj Vaccines, 2021
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80–90% genome sequence identity.
Yara Ruiz García, Woo-Yun Sohn, Kate L. Seib, Muhamed-Kheir Taha, Julio A. Vázquez, Ana Paula S. de Lemos, Kumaran Vadivelu, Mariagrazia Pizza, Rino Rappuoli, Rafik Bekkat-Berkani   +9 more
doaj   +1 more source

Safety and Immunogenicity of Meningococcal Groups A and C Polysaccharide Vaccine in Adults 18–60 years of age

Эпидемиология и вакцинопрофилактика, 2023
Relevance. In the Russian Federation, despite the low incidence rate in 2020–2021, there are subjects where the incidence rate of meningococcal infection (MI) exceeds the national average by 2–9 times.
V. V. Romanenko, B. I. Kuzubov, N. A. Tsukanova, A. A. Kotova   +3 more
doaj   +1 more source

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review

Infectious Diseases and Therapy, 2019
Neisseria meningitidis is a major cause of meningitis and septicemia with cases, outbreaks, and epidemics reported globally in industrialized and non-industrialized countries. N. meningitidis is categorized into 12 serogroups; however, only 5 serogroups (
Jessica Presa, Jamie Findlow, Jelena Vojicic, Scott Williams, Lidia Serra   +4 more
doaj   +1 more source

Vaccines against Meningococcal Diseases

Microorganisms, 2020
Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza, Rafik Bekkat-Berkani, Rino Rappuoli   +2 more
doaj   +1 more source

The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. [PDF]

PLoS Medicine, 2018
BACKGROUND:The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt.
Reza Yaesoubi, Caroline Trotter, Caroline Colijn, Maziar Yaesoubi, Anaïs Colombini, Stephen Resch, Paul A Kristiansen, F Marc LaForce, Ted Cohen   +8 more
doaj   +1 more source

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Hypervirulent serogroup W meningococcal strain belonging to the ST-11 clonal complex is associated with higher case fatality rates: Nationwide cohort study of invasive meningococcal disease caused by serogroup W in England from 2010-2019

Journal of Infection
Summary: Background: In 2009, England experienced an increase in serogroup W (MenW) invasive meningococcal disease (IMD) caused by the hypervirulent ST-11 clonal complex (MenW:cc11) South American strain sublineage.
Catherine Isitt, Helen Campbell, Jay Lucidarme, Stephen A. Clark, Paul T. Heath, Ray Borrow, Shamez N. Ladhani   +6 more
doaj   +1 more source

Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection

Canadian Journal of Infectious Diseases and Medical Microbiology, 2009
Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children.
Nicole Le Saux, Julie A Bettinger, Susan Wootton, Scott A Halperin, Wendy Vaudry, David W Scheifele, Raymond Tsang   +6 more
doaj   +1 more source

Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. [PDF]

PLoS ONE, 2012
Neisseria meningitidis is a major global pathogen causing invasive disease with a mortality of 5-10%. Most disease in developed countries is caused by serogroup B infection, against which there is no universal vaccine.
Manish Sadarangani, J Claire Hoe, Martin J Callaghan, Claire Jones, Hannah Chan, Katherine Makepeace, Hélène Daniels-Treffandier, Mary E Deadman, Christopher Bayliss, Ian Feavers, Peter van der Ley, Andrew J Pollard   +11 more
doaj   +1 more source

Improving detection of secondary immunodeficiency and vaccination after invasive airway infections: a prospective cohort study with retrospective comparison

Internal Medicine Journal, EarlyView.
Abstract Background Infections caused by encapsulated pathogens such as Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis contribute to significant morbidity and mortality, with immunodeficiency being an important risk factor for recurrent and invasive disease.
B. Tan, M. Metlapalli, M. Liu, D. Kotsanas, E. L. Smith, S. Ojaimi   +5 more
wiley   +1 more source